Young-onset amyotrophic lateral sclerosis: Historical and other observations

Brain

Volumn 135, Issue 9, 2012, Pages 2883-2891

  Turner, Martin R ^a   Barnwell, Jessica ^b   Al Chalabi, Ammar ^b   Eisen, Andrew ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

bulbar; evolution; juvenile; life expectancy; motor neuron disease

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; APATHY; ARTICLE; CHILDHOOD; DISEASE COURSE; ENVIRONMENTAL FACTOR; EPIGENETICS; FAMILY HISTORY; FRONTOTEMPORAL DEMENTIA; GENOTYPE; HUMAN; INFANCY; LAMINECTOMY; LIFE EXPECTANCY; LOSS OF FUNCTION MUTATION; ONSET AGE; PHENOTYPE; PRIMARY LATERAL SCLEROSIS; PRIORITY JOURNAL; PROGRESSIVE MUSCULAR ATROPHY; SEX DIFFERENCE; SYMPTOM; YOUNG ONSET AMYOTROPHIC LATERAL SCLEROSIS;

EID: 84866426340     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aws144     Document Type: Article

References (124)

1. Aggarwal A, Nicholson G. Normal complement of motor units in asymptomatic familial (SOD1 mutation) amyotrophic lateral sclerosis carriers. J Neurol Neurosurg Psychiatry 2001; 71: 478-81.
2. Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol 2011; 7: 603-15.
3. Appenzeller O, Stevens JM, Kruszynski R, Walker S. Neurology in ancient faces. J Neurol Neurosurg Psychiatry 2001; 70: 524-9.
4. Armon C. Epidemiology of amyotrophic lateral sclerosis/motor neuron disease. In: Shaw P, Strong MJ, editors. Motor Neuron Disorders. Philadelphia, PA: Elsevier Inc; 2003. p. 167-205.
5. Armon C. Smoking may be considered an established risk factor for sporadic ALS. Neurology 2009; 73: 1693-8.
6. Baumer D, Hilton D, Paine SM, Turner MR, Lowe J, Talbot K, et al. Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology 2010; 75: 611-8.
7. Beevor C. A case of amyotrophic lateral sclerosis with clonus of the lower jaw. Brain 1886; 8: 516-9.
8. Beghi E, Millul A, Micheli A, Vitelli E, Logroscino G. Incidence of ALS in Lombardy, Italy. Neurology 2007; 68: 141-5.
9. Blair IP, Bennett CL, Abel A, Rabin BA, Griffin JW, Fischbeck KH, et al. A gene for autosomal dominant juvenile amyotrophic lateral sclerosis (ALS4) localizes to a 500-kb interval on chromosome 9q34. Neurogenetics 2000; 3: 1-6.
10. Boukaftane Y, Khoris J, Moulard B, Salachas F, Meininger V, Malafosse A, et al. Identification of six novel SOD1 gene mutations in familial amyotrophic lateral sclerosis. Can J Neurol Sci 1998; 25: 192-6.
11. Byrne S, Elamin M, Bede P, Shatunov A, Walsh C, Corr B, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol 2012; 11: 232-40.
12. Calne DB, Eisen A, McGeer E, Spencer P. Alzheimer's disease, Parkinson's disease, and motoneurone disease: abiotrophic interaction between ageing and environment? Lancet 1986; 2: 1067-70.
13. Canudas-Romo V. Three measures of longevity: time trends and record values. Demography 2010; 47: 299-312.
14. Charcot J-M. Sclérose des cordons latéraux de la moelle épinière chez une femme hysté rique atteinte de contracture permanente des quatre membres. Bull Mém Soc Méd Hôp Paris 1865; 10: 24-35.
15. Charcot J-M, Joffroy A. Deus cas d'atrophie musculaire progressive avec lesions de la substance grise et des faisceaux antéro-laté rale. Arch Physiol 1869; 2: 354-7, 744-60.
16. Chen YZ, Bennett CL, Huynh HM, Blair IP, Puls I, Irobi J, et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet 2004; 74: 1128-35.
17. Chio A, Borghero G, Restagno G, Mora G, Drepper C, Traynor BJ, et al. Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Brain 2012; 135: 784-93.
18. Chio A, Calvo A, Moglia C, Mazzini L, Mora G. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2011a; 82: 740-6.
19. Chio A, Canosa A, Gallo S, Moglia C, Ilardi A, Cammarosano S, et al. Pain in amyotrophic lateral sclerosis: a population-based controlled study. Eur J Neurol 2011b; 19: 551-5.
20. Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 2009; 10: 310-23.
21. Clarke L, Jackson HJ. On a case of muscular atrophy with disease of the spinal cord and medulla oblongata. Med Chir Trans 1867; 50: 489-498.
22. Collins J. Amyotrophic lateral sclerosis. Am J Med Sci 1903; 125: 939-66.
23. Cooper G. On atrophy or degeneration of the muscles of the upper and lower extremities. Med Chir Trans 1886; 49: 171-4.
24. Cooper-Knock J, Hewitt C, Highley JR, Brockington A, Milano A, Man S, et al. Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain 2012; 135(Pt 3): 751-64.
25. Cruveilhier J. Sur la paralysie musculaire progressive atrophique. Arch Gen Med 1853; 1: 561.
26. Czaplinski A, Yen AA, Appel SH. Amyotrophic lateral sclerosis: early predictors of prolonged survival. J Neurol 2006; 253: 1428-36.
27. David A, Zimmerman MR. Cancer: an old disease, a new disease or something in between? Nat Rev Cancer 2010; 10: 728-32.
28. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked frontotemporal dementia and ALS. Neuron 2011; 72: 245-56.
29. Dercum F, Spiller WG. A case of amyotrophic lateral sclerosis presenting bulbar symptoms with necropsy and microscopical examination. J Nerv Ment Dis 1899; 26: 84-106.
30. Doi Y, Yokoyama T, Tango T, Takahashi K, Fujimoto K, Nakano I. Temporal trends and geographic clusters of mortality from amyotrophic lateral sclerosis in Japan, 1995-2004. J Neurol Sci 2010; 298: 78-84.
31. Eisen A. The real onset of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011; 82: 593.
32. Eisen A, Krieger C. Amyotrophic lateral sclerosis: a synthesis of research and clinical practice. Cambridge, UK: Cambridge University Press; 1998.
33. Eisen A, Schulzer M, MacNeil M, Pant B, Mak E. Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve 1993; 16: 27-32.
34. Falconer DS. The inheritance of liability to diseases with variable age of onset, with particular reference to diabetes mellitus. Ann Hum Genet 1967; 31: 1-20.
35. Ferrier S. Cases of amyotrophic lateral sclerosis. Lancet 1881; 117: 822-3.
36. Frank SA. Evolution in health and medicine Sackler colloquium: somatic evolutionary genomics: mutations during development cause highly variable genetic mosaicism with risk of cancer and neu-rodegeneration. Proc Natl Acad Sci USA 2010; 107 (Suppl 1): 1725-30.
37. General Lifestyle Survey. Smoking and drinking among adults, 2009. Newport: Office for National Statistics; 2011. Gibson G. Bulbar paralysis and its counterfeits. BMJ 1900; 1: 1009-12.
38. Goldacre MJ, Duncan M, Griffith M, Turner MR. Trends in death certification for multiple sclerosis, motor neuron disease, Parkinson's disease and epilepsy in English populations 1979-2006. J Neurol 2010; 257: 706-15.
39. Gordon R, Delicati JL. The occurrence of amyotrophic lateral sclerosis in children. J Neurol Psychopathol 1928; 9: 30-5.
40. Gorman AM. Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling. J Cell Mol Med 2008; 12: 2263-80.
41. Gouveia LO, de Carvalho M. Young-onset sporadic amyotrophic lateral sclerosis: a distinct nosological entity? Amyotroph Lateral Scler 2007; 8: 323-7.
42. Gowers W. A lecture on abiotrophy. Lancet 1902; 1: 1003-7.
43. Guthrie L, Fearnsides EG. Amyotrophic lateral sclerosis in a man aged 28 showing Chvostek's sign. Proc R Soc Med 1916; 9: 71-2.
44. Hadano S, Yanagisawa Y, Skaug J, Fichter K, Nasir J, Martindale D, et al. Cloning and characterization of three novel genes, ALS2CR1, ALS2CR2, and ALS2CR3, in the juvenile amyotrophic lateral sclerosis (ALS2) critical region at chromosome 2q33-q34: candidate genes for ALS2. Genomics 2001; 71: 200-13.
45. Handy CR, Krudy C, Boulis N, Federici T. Pain in amyotrophic lateral sclerosis: a neglected aspect of disease. Neurol Res Int 2011; 2011: 403808.
46. Hassin GB. Bulbar paralysis or amyotrophic lateral sclerosis? A clinico-pathologic note. Arch Neurol Psychiatry 1919; 2: 261-71.
47. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995; 118(Pt 3): 707-19.
48. Hayward C, Brock DJ, Minns RA, Swingler RJ. Homozygosity for Asn86Ser mutation in the CuZn-superoxide dismutase gene produces a severe clinical phenotype in a juvenile onset case of familial amyotrophic lateral sclerosis. J Med Genet 1998; 35: 174.
49. Hechst B. Zur pathohistologie und pathogenese der amyotrophischen lateralsklerose. Archiv fur Psychiatrie und Nervenkrankheiten 1931; 93: 159-81.
50. Hektoen L. Amyotrophic lateral sclerosis with bulbar paralysis and degeneration in Goll's columns: a contribution to the pathology of the primary combined system diseases. J Nerv Ment Dis 1895; 20: 145-77.
51. Huang Q, Figueiredo-Pereira ME. Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications. Apoptosis 2010; 15: 1292-311.
52. Huisman MH, de Jong SW, van Doormaal PT, Weinreich SS, Schelhaas HJ, van der Kooi AJ, et al. Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J Neurol Neurosurg Psychiatry 2011; 82: 1165-70.
53. Jellinger KA. Recent advances in our understanding of neurodegenera-tion. J Neural Transm 2009; 116: 1111-62.
54. Johnston CA, Stanton BR, Turner MR, Gray R, Blunt AH, Butt D, et al. Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol 2006; 253: 1642-3.
55. Jokelainen M. Amyotrophic lateral sclerosis in Finland. I: an epidemiolo-gic study. Acta Neurol Scand 1977a; 56: 185-93.
56. Jokelainen M. Amyotrophic lateral sclerosis in Finland. II: clinical characteristics. Acta Neurol Scand 1977b; 56: 194-204.
57. Kahler O, Pick A. Beitrage zur Pathologie und pathologischen Anatomie des Centralnervensystems. Vierteljahresschrift fur die praktische Heilkunde. Vol. 141. Prague; 1879. p. 1-86.
58. Kato M, Aoki M, Ohta M, Nagai M, Ishizaki F, Nakamura S, et al. Marked reduction of the Cu/Zn superoxide dismutase polypeptide in a case of familial amyotrophic lateral sclerosis with the homozygous mutation. Neurosci Lett 2001; 312: 165-8.
59. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet 2011; 377: 942-55.
60. Kojewnikoff A. Cas de sclerose laterale amyotrophique, la degenerescence des faisceaux pyramidaux se propageant a travers tout l'encephale. Arch Neurol 1883; 6: 356-76.
61. Lelong J, Lereboullet J, Merklen FP. Amyotrophic lateral sclerosis in a girl 16 years old. Bull Soc de Pediat de Paris 1932; 30: 88-93.
62. Lesnick TG, Sorenson EJ, Ahlskog JE, Henley JR, Shehadeh L, Papapetropoulos S, et al. Beyond Parkinson disease: amyotrophic lateral sclerosis and the axon guidance pathway. PLoS One 2008; 3: e1449.
63. Lewis R. Cases of amyotrophic lateral sclerosis. A Mirror of Hospital Practice, British and Foreign 1880; 4: 1.
64. Li Q, Spencer NY, Pantazis NJ, Engelhardt JF. Alsin and SOD1(G93A) proteins regulate endosomal reactive oxygen species production by glial cells and proinflammatory pathways responsible for neurotoxicity. J Biol Chem 2011; 286: 40151-62.
65. Li TM, Swash M, Alberman E. Morbidity and mortality in motor neuron disease: comparison with multiple sclerosis and Parkinson's disease: age and sex specific rates and cohort analyses. J Neurol Neurosurg Psychiatry 1985; 48: 320-7.
66. Li TM, Swash M, Alberman E, Day SJ. Diagnosis of motor neuron disease by neurologists: a study in three countries. J Neurol Neurosurg Psychiatry 1991; 54: 980-3.
67. Logroscino G, Beghi E, Zoccolella S, Palagano R, Fraddosio A, Simone IL, et al. Incidence of amyotrophic lateral sclerosis in southern Italy: a population based study. J Neurol Neurosurg Psychiatry 2005; 76: 1094-8.
68. Logroscino G, Traynor BJ, Hardiman O, Chio A, Mitchell D, Swingler RJ, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010; 81: 385-90.
69. Mackay R. Course and prognosis in amyotrophic lateral sclerosis. Arch Neurol 1963; 8: 117-27.
70. Mackenzie IR, Ansorge O, Strong M, Bilbao J, Zinman L, Ang LC, et al. Pathological heterogeneity in amyotrophic lateral sclerosis with FUS mutations: two distinct patterns correlating with disease severity and mutation. Acta Neuropathol 2011a; 122: 87-98.
71. Mackenzie IR, Munoz DG, Kusaka H, Yokota O, Ishihara K, Roeber S, et al. Distinct pathological subtypes of FTLD-FUS. Acta Neuropathol 2011b; 121: 207-18.
72. Majounie E, Renton AE, Mok K, Dopper EGP, Waite A, Rollinson S, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012; 11: 297-8.
73. Manning JT, Bundred PE. The ratio of 2nd to 4th digit length: a new predictor of disease predisposition? Med Hypotheses 2000; 54: 855-7.
74. Marie P. Cas de sclerose laterale amyotrophique avec autopsie. C R de la Soc de Biol 1883; 4: 3-15.
75. Marie P, Bouttier H, Bertrand I. Anatomic study of a case of amyotrophic sclerosis with Hemiplegia. Bull et mem Soc med d hop de Par 1923; 47: 481-5.
76. Marin B, Kacem I, Diagana M, Boulesteix M, Gouider R, Preux PM, et al. Juvenile and adult-onset ALS/MND among Africans: incidence, phenotype, survival: a review. Amyotroph Lateral Scler 2012; 13: 276-83.
77. McComas AJ, Fawcett PR, Campbell MJ, Sica RE. Electrophysiological estimation of the number of motor units within a human muscle. J Neurol Neurosurg Psychiatry 1971; 34: 121-31.
78. McGuire V, Nelson LM. Epidemiology of ALS. In: Mitsumoto H, Przedborksi S, Gordon PH, editors. Amyotrophic lateral sclerosis. New York, NY: Taylor & Francis; 2006. p. 17-41.
79. McPhedran A. A case of amyotorphic lateral sclerosis. Am Med 1903; 12: 2-12.
80. Mott F. A case of amyotrophic lateral sclerosis with degeneration of the motor path from the cortex to the periphery. Brain 1895; 18: 21-36.
81. Nalini A, Thennarasu K, Gourie-Devi M, Shenoy S, Kulshreshtha D. Clinical characteristics and survival pattern of 1, 153 patients with amyotrophic lateral sclerosis: experience over 30 years from India. J Neurol Sci 2008; 272: 60-70.
82. O'Toole O, Traynor BJ, Brennan P, Sheehan C, Frost E, Corr B, et al. Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004. J Neurol Neurosurg Psychiatry 2008; 79: 30-2.
83. Orban P, Devon RS, Hayden MR, Leavitt BL. Juvenile amyotrophic lateral sclerosis. In: Eisen A, Shaw PJ, editors. Handbook of clinical neurology, motor neuron disorders and related disorders. Vol. 82. Amsterdam: Elsevier B.V.; 2007. p. 301-12.
84. Orlacchio A, Babalini C, Borreca A, Patrono C, Massa R, Basaran S, et al. SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. Brain 2010; 133: 591-8.
85. Ormerod J. Amyotrophic lateral sclerosis. Brain 1886; 9: 245-57.
86. Ors Y. Evolution, environment and cancer. Proc R Soc Med 1977; 70: 753-54.
87. Otomo A, Kunita R, Suzuki-Utsunomiya K, Ikeda JE, Hadano S. Defective relocalization of ALS2/alsin missense mutants to Rac1-induced macropinosomes accounts for loss of their cellular function and leads to disturbed amphisome formation. FEBS Lett 2011; 585: 730-6.
88. Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol 2007; 6: 994-1003.
89. Polymenidou M, Cleveland DW. The seeds of neurodegeneration: prion-like spreading in ALS. Cell 2011; 147: 498-508.
90. Prates C, Sousa S, Oliveira C, Ikram S. Prostate metastatic bone cancer in an Egyptian Ptolemaic mummy, a proposed radiological diagnosis. Int J Paleopath 2011; 1: 98-103.
91. Radcliffe C, Lockhart Clarke J. An important case of paralysis and muscular atrophy with disease of the nervous centres. Br Foreign Med-Chir Rev 1862; 30: 215-25.
92. Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology 2009; 73: 805-11.
93. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-frontotemporal dementia. Neuron 2011; 72: 257-68.
94. Ritchie K, Kildea D. Is senile dementia "age-related" or "ageing-related"?-evidence from meta-analysis of dementia prevalence in the oldest old. Lancet 1995; 346: 931-4.
95. Roberts W. An essay on wasting palsy (Cruveilhier's atrophy). London: Churchill; 1858.
96. Rosen AD. Amyotrophic lateral sclerosis. Clinical features and prognosis. Arch Neurol 1978; 35: 638-42.
97. Rovighi A, Melloti G. Contribuzione allo studio della sclerosi laterale amiotrofica. Rivista sperimentale di frenetria e medicina legale della alienazioni mentali 1888; 14: 315-8.
98. Rowland LP. How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot. Arch Neurol 2001; 58: 512-5.
99. Sabatelli M, Madia F, Conte A, Luigetti M, Zollino M, Mancuso I, et al. Natural history of young-adult amyotrophic lateral sclerosis. Neurology 2008; 71: 876-81.
100. Shaw JC. A case of progressive muscular atrophy with sclerosis of the lateral columns. J Nerv Ment Dis 1879; 6: 56-65.
101. Simó n-Sánchez J, Dopper EG, Cohn-Hokke PE, Hukema RK, Nicolaou N, Seelaar H, et al. The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain 2012; 135 (Pt 3): 723-35.
102. Spillane JD. The clinical aspects. Proc R Soc Med 1962; 55: 1019-20.
103. Stein CR, Ellis JA, Savitz DA, Vichinsky L, Perl SB. Decline in smoking during pregnancy in New York City, 1995-2005. Public Health Rep 2009; 124: 841-9.
104. Sutedja NA, Veldink JH, Fischer K, Kromhout H, Heederik D, Huisman MH, et al. Exposure to chemicals and metals and risk of amyotrophic lateral sclerosis: a systematic review. Amyotroph Lateral Scler 2009; 10: 302-9.
105. Thomas T. The treatment of progressive muscular atrophy with parathyroid, calcium, and vitamin D. BMJ 1928; 1: 978-9.
106. Turner BM. Epigenetic responses to environmental change and their evolutionary implications. Philos Trans R Soc Lond B Biol Sci 2009; 364: 3403-18.
107. Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002; 3: 15-21.
108. Turner MR, Swash M, Ebers GC. Lockhart Clarke's contribution to the description of amyotrophic lateral sclerosis. Brain 2010; 133: 3470-9.
109. Turner MR, Wicks P, Brownstein CA, Massagli MP, Toronjo M, Talbot K, et al. Concordance between site of onset and limb dominance in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011; 82: 853-4.
110. Vargas MR, Johnson JA. Astrogliosis in amyotrophic lateral sclerosis: role and therapeutic potential of astrocytes. Neurotherapeutics 2010; 7: 471-81.
111. Veltema AN. The case of the saltimbanque Prosper Lecomte. A contribution to the study of the history of progressive muscular atrophy (Aran-Duchenne) and amyotrophic lateral sclerosis (Charcot). Clin Neurol Neurosurg 1975; 78: 204-9.
112. Vivekananda U, Manjalay ZR, Ganesalingam J, Simms J, Shaw CE, Leigh PN, et al. Low index-to-ring finger length ratio in sporadic ALS supports prenatally defined motor neuronal vulnerability. J Neurol Neurosurg Psychiatry 2011; 82: 635-7.
113. Vucic S, Nicholson GA, Kiernan MC. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain 2008; 131: 1540-50.
114. Warner JD. A contribution to the histopathology of amyotrophic lateral sclerosis. J Nerv Ment Dis 1926; 64: 229-34.
115. Wechsler I, Sapirstein MR, Stein A. Primary and symptomatic amyotrophic lateral sclerosis: a clinical study of 81 cases. Am J Med Sci 1944; 208: 70-81.
116. Wechsler IS, Brock S, Weil A. Amyotrophic lateral sclerosis with objective and subjective (neuritic) sensory disturbances. Arch Neurol Psychiatry 1929; 21: 299-310.
117. Wechsler IS, Dvison C. Amyotrophic lateral sclerosis with mental symptoms. Arch Neurol Psychiatry 1932; 27: 859-80.
118. Weidong L, Shen C, Jankovic J. Etiopathogenesis of Parkinson disease: a new beginning? Neuroscientist 2009; 15: 28-35.
119. Willis M. Amyotrophic lateral sclerosis. J Nerv Ment Dis 1895; 20: 793-5.
120. Wilmoth Jr. The future of human longevity: a demographer's perspective. Science 1998; 280: 395-7.
121. Wilmoth JR, Deegan LJ, Lundstrom H, Horiuchi S. Increase of maximum life-span in Sweden, 1861-1999. Science 2000; 289: 2366-8.
122. Wohlfart G. Collateral regeneration in partially denervated muscles. Neurology 1958; 8: 175-80.
123. Ziegler LH. Psychotic and emotional phenomena associated with amyo-trophic lateral sclerosis. Arch Neurol Psychiatry 1930; 24: 930-6.
124. Zinman L, Liu HN, Sato C, Wakutani Y, Marvelle AF, Moreno D, et al. A mechanism for low penetrance in an ALS family with a novel SOD1 deletion. Neurology 2009; 72: 1153-9.